Skip to main content
. 2021 Jan 27;89:104717. doi: 10.1016/j.meegid.2021.104717

Table 1.

Clinical features and treatment regimens of Covid-19 patients (n = 284).

Age (years) 49 (19–92)
Sex (female vs males) 128/ 156 (45.1% vs 54.9%)
Co-morbid diseases
 Hypertension 72 (24.5%)
 Diabetes mellitus 36 (12.7%)
 Chronic obstructive pulmonary disease 30 (10.6%)
 Coronary artery disease 17 (6.0%)
 Congestive heart failure 5 (1.8%)
 Solid malignancy 26 (9.2%)
 Hematological malignancy 7 (2.5%)
Clinical course
 Severe vs mild 94/190 (33.1% vs 66.9%)
Symptoms
 Dry cough 170 (59.9%)
 Fever 154 (54.2%)
 Myalgia 145 (51.1%)
 Dyspnea 94 (33.1%)
 Nausea/vomitus 30 (10.6%)
 Diarrhea 23 (8.1%)
 Anosmia/dysgeusia 13 (4.6%)
 Sputum 1 (0.4%)
Physical examination findings on admission
 Fever 94/190 (33.1%/66.9%)
 Body temperature 36.6 (35–40)
 Saturation pO2 (peripheral) 97 (87–100)
 Systolic blood pressure 130 (90–240)
 Diastolic blood pressure 75 (50–100)
 Pulse (/min) 92 (60–160)
 Respiratory rate (/min) 16 (12–40)
Laboratory evaluation
 pH 7.41 (7.1–8.1)
 pO2 62 (35–86)
 pCO2 40 (23–63)
 HCO3 24 (14–35)
 Lactate 1.5 (1–7)
 Hemoglobin (g/dL) 13.2 (6.3–18)
 Leukocyte (/mm3) 7130 (930–28,300)
 Thrombocyte (/mm3) 241,000 (66000–576,000)
 Lymphocyte (/mm3) 1390 (270–4520)
 Lymphopenia (<800/mm3) 57 (20.1%)
 BUN (mg/dL) 13 (5–107)
 Creatinine (mg/dL) 0.8 (0.4–6)
 Glucose (mg/dL) 106 (68–496)
 AST (U/L) 21 (10–409)
 ALT (U/L) 21 (2–493)
 GGT (U/L) 21 (4–744)
 ALP (U/L) 73 (33–400)
 LDH (U/L) 194 (78–731)
 Total protein (g/dL) 7.4 (5–9)
 Albumin (g/dL) 4.0 (2–5)
 CRP (mg/dL) 19.5 (1–363)
 Procalcitonin (ng/mL) 0.06 (0.2–50.0)
 Ferritin 166 (6–6656)
 D-dimer 58 (5–35,000)
 Troponin-T 4 (3–848)
 Fibrinogen 423 (151–1053)
 INR 0.9 (0.8–3.8)
 aPTT 28 (21–53)
Follow-up
 Mortality (at 28 days) 9 (3.2%)
 Intensive care unit need 16 (6.3%)

Data are given as numbers (%) or median (interquartile range).